{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-053294","form_type":"8-K","ticker":"SANA","cik":"0001770121","company_name":"Sana Biotechnology, Inc.","filed_at":"2026-02-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.117993+00:00","generated_at":"2026-05-16T02:29:29.873529+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Sana Biotechnology appoints Brian Piper as EVP, CFO; base salary $515K, option grant of 900K shares","bullets":["Brian Piper appointed EVP, CFO and Treasurer effective February 17, 2026; replaces Steven Harr as acting principal financial officer.","Annual base salary of $515,000 with target bonus of 40% of base salary.","Granted option to purchase 900,000 shares (25% vest year 1, then monthly) and 200,000 RSUs (4-yr annual vest).","Piper previously CFO at Scorpion Therapeutics, Antares Therapeutics, and Prelude Therapeutics; over 25 years biopharma finance experience.","Company expects initial clinical data for SC451 (type 1 diabetes) and SG293 (B-cell disease) in next 12-18 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-053294","json":"https://secwatch.observer/filing/0001193125-26-053294.json","markdown":"https://secwatch.observer/filing/0001193125-26-053294.md","text":"https://secwatch.observer/filing/0001193125-26-053294.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1770121/000119312526053294/0001193125-26-053294-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1770121/000119312526053294/sana-20260217.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T02:29:29.873529+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}